Celgene's Otezla shows meaningful improvements in plaque psoriasis study

US biotech firm Celgene Corp (Nasdaq: CELG), via its European unit Celgene International Sàrl, said its Otezla (apremilast), to treat plaque psoriasis has shown meaningful improvements.

The company said 40% patients receiving Otezla 30mg twice daily, at week 16, demonstrated statistically significant improvements compared with 12% patients on placebo in the primary endpoint.

Kristian Reich, SCIderm Research Institute and Dermatologikum Hamburg, Germany, said: “Many patients with moderate to severe plaque psoriasis need treatment options that can help in managing multiple facets of the disease, including itching and impact on disease-related quality of life. The encouraging findings presented at EADV add to the growing body of data which suggest that treatment benefits observed with Otezla at week 16 are maintained through week 52 of treatment.”